文献速递基础与转化研究临床试验与 GCP

慢病毒基因治疗脑型肾上腺脑白质营养不良

Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy.
PubMed 文献 · N Engl J Med · 2024-01-01

这项2-3期研究评估了eli-cel基因治疗对早期脑型肾上腺脑白质营养不良且MRI显示活动性炎症男孩的疗效与安全性。32例接受治疗,24个月时29例完成研究且均无主要功能障碍,总生存率94%;中位随访6年时30/32例神经功能评分稳定,26例无主要功能障碍,但1例在92个月时发生伴原始细胞增多的骨髓增生异常综合征。

要点

  • 24个月时29例完成研究者均无主要功能障碍,总生存率94%。
  • 中位随访6年时30/32例(94%)神经功能评分稳定,26例(81%)无主要功能障碍。
  • 1例在92个月时发生伴原始细胞增多的骨髓增生异常综合征,接受异基因造血干细胞移植后最近随访无MDS。

核心结论

  • 在中位随访6年的慢病毒基因治疗后,多数早期脑型肾上腺脑白质营养不良且MRI异常的患者无主要功能障碍,但病毒载体整合相关的插入性致癌作用仍是持续存在的风险。

研究设计与样本

  • 2-3期研究,评估eli-cel基因治疗对早期脑型肾上腺脑白质营养不良且MRI显示活动性炎症男孩的疗效与安全性。
  • eli-cel由经含ABCD1互补DNA的Lenti-D慢病毒载体转导的自体CD34+细胞组成。
  • 主要疗效终点为24个月时无六项主要功能障碍中任一项的生存;次要终点包括24个月总生存率及从基线至24个月总神经功能评分变化。
  • 共32例患者接受eli-cel,其中29例(91%)完成24个月研究并进入长期随访研究。

主要发现

  • 24个月时,完成研究的29例患者均无主要功能障碍,总生存率为94%。
  • 最近一次评估(中位随访6年)时,32例中30例(94%)神经功能评分较基线稳定,26例(81%)无主要功能障碍。
  • 4例患者发生与eli-cel直接相关的不良事件。
  • 1例患者在92个月时发生伴原始细胞增多的骨髓增生异常综合征(MDS),接受异基因造血干细胞移植,最近随访时无MDS。

局限性

  • 插入性致癌作用是与病毒载体整合相关的持续存在的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cerebral adrenoleukodystrophy is a severe form of X-linked adrenoleukodystrophy characterized by white-matter disease, loss of neurologic function, and early death. Elivaldogene autotemcel (eli-cel) gene therapy, which consists of autologous CD34+ cells transduced with Lenti-D lentiviral vector containing ABCD1 complementary DNA, is being tested in persons with cerebral adrenoleukodystrophy. METHODS: In a phase 2-3 study, we evaluated the efficacy and safety of eli-cel therapy in boys with early-stage cerebral adrenoleukodystrophy and evidence of active inflammation on magnetic resonance imaging (MRI). The primary efficacy end point was survival without any of six major functional disabilities at month 24. The secondary end points included overall survival at month 24 and the change from baseline to month 24 in the total neurologic function score. RESULTS: A total of 32 patients received eli-cel; 29 patients (91%) completed the 24-month study and are being monitored in the long-term follow-up study. At month 24, none of these 29 patients had major functional disabilities; overall survival was 94%. At the most recent assessment (median follow-up, 6 years), the neurologic function score was stable as compared with the baseline score in 30 of 32 patients (94%); 26 patients (81%) had no major functional disabilities. Four patients had adverse events that were directly related to eli-cel. Myelodysplastic syndrome (MDS) with excess blasts developed in 1 patient at month 92; the patient underwent allogeneic hematopoietic stem-cell transplantation and did not have MDS at the most recent follow-up. CONCLUSIONS: At a median follow-up of 6 years after lentiviral gene therapy, most patients with early cerebral adrenoleukodystrophy and MRI abnormalities had no major functional disabilities. However, insertional oncogenesis is an ongoing risk associated with the integration of viral vectors. (Funded by Bluebird Bio; ALD-102 and LTF-304 ClinicalTrials.gov numbers NCT01896102 and NCT02698579, respectively.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Eichler F, Duncan CN, Musolino PL, et al. Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy. N Engl J Med. 2024. PMID: 39383459. doi:10.1056/NEJMoa2400442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。